0.8855 0.00 (0.00%)
Pre-Market: 6:23AM EDT
|Bid||0.0000 x 900|
|Ask||0.0000 x 800|
|Day's Range||0.8300 - 0.9500|
|52 Week Range||0.8100 - 6.7500|
|Beta (3Y Monthly)||0.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Every investor in BioPharmX Corporation (NYSEMKT:BPMX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend toRead More...
BioPharmX Corporation (NYSEMKT:BPMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BPMX will Read More...
The big shareholder groups in BioPharmX Corporation (NYSEMKT:BPMX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies.Read More...
On July 19, specialty dermatology player BioPharmX (BPMX) announced that the FDA had waived the dermal carcinogenicity study it had required as part of the development program for BPX-01. BPX-01 is BioPharmX’s investigational topical minocycline gel for the treatment of patients suffering from inflammatory lesions due to acne vulgaris. The waiver implies that BioPharmX will save in terms of the time and resources that would have been required for the nonclinical research normally done for the FDA review.